Business
Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing Services
Represents first project to enter the ECO Synthesis™ Innovation Lab Core enzymes for ECO Synthesis™ technology have transitioned from research into
About this update from Codexis, Inc.
[{"type":"text","content":"Represents first project to enter the ECO Synthesis™ Innovation Lab Core enzymes for ECO Synthesis™ technology have transitioned from research into development and scale-up as the first step in securing the raw materials supply chain REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced its first revenue-generating contract to manufacture siRNA material in its ECO Synthesis™ Innovation Lab. Codexis has also successfully completed development of the first generation of its core ECO Synthesis™ enzymes, having met the pre-specified criteria to support scaling to industrial capacity. “We are excited to sign this first revenue-generating contract for ECO Synthesis™, which builds on our previous success with our dsRNA ligation offering,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “I’m also delighted that our research organization has successfully built a suite of enzymes capable of driving the ECO Synthesis™ platform at industrial scale. We look forward to demonstrating process parameters comparable with or better than chemical methods at upcoming scientific meetings.” About Codexis Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statemen...